Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183360 | 0.80 | BRD4 (0.48) | ALDH1A1LMNARAB9AESR1ESR2 | |
| SCHEMBL1079975 | 0.70 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAKMT2ARAB9A | |
| SCHEMBL31229354 | 0.70 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAKMT2ARAB9A | |
| SCHEMBL31583802 | 0.70 | ESR1 (0.43) | KDM4EKMT2AESR1ESR2BRD4 | |
| SCHEMBL10924592 | 0.70 | KDM4E (0.43) | ALDH1A1KDM4ELMNAKMT2ATDP1 | |
| SCHEMBL10708179 | 0.69 | ESR1 (0.44) | ALDH1A1KDM4ELMNAKMT2ARAB9A | |
| SCHEMBL9757419 | 0.69 | KDM4E (0.51) | ALDH1A1KDM4ELMNAKMT2ARAB9A | |
| SCHEMBL4621097 | 0.68 | TDP1 (0.43) | ALDH1A1KDM4ELMNAKMT2ATDP1 | |
| SCHEMBL21326790 | 0.68 | ESR1 (0.44) | ALDH1A1KDM4ELMNAKMT2ARAB9A | |
| SCHEMBL27813078 | 0.68 | TSHR (0.40) | ALDH1A1KDM4ELMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439356-B2 | Substituted indan derivatives | ASTRAZENECA AB (SE) | 2008-10-21 | — | — | US | disclosed |
| US-7439356-B2 | Substituted indan derivatives | ASTRAZENECA AB (SE) | 2008-10-21 | — | — | US | disclosed |
| US-20070149545-A1 | Substituted indan derivatives | BERG STEFAN | 2007-06-28 | — | — | US | disclosed |
| US-20070149545-A1 | Substituted indan derivatives | BERG STEFAN | 2007-06-28 | — | — | US | disclosed |
| US-20050096326-A1 | Substituted indian derivatives | BERG STEFAN (SE) | 2005-05-05 | — | — | US | disclosed |
| EP-1025094-B1 | SUBSTITUTED INDAN DERIVATIVES | ASTRAZENECA AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| US-20030144291-A1 | Substituted indan derivatives | BERG STEFAN (SE) | 2003-07-31 | — | — | US | disclosed |
| US-6548498-B1 | 4-(piperazino)-indan derivatives; 5-hydroxytryptamine receptor (h5-HT1B-receptor) antagonists; use treating psychological disorders, obesity, nervous system disorders and as antitumor agent | ASTRAZENECA AB (SE) | 2003-04-15 | — | — | US | disclosed |
| EP-1025094-A1 | SUBSTITUTED INDAN DERIVATIVES | Astrazeneca AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999014207-A1 | SUBSTITUTED INDAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096326-A1 | Substituted indian derivatives | HTR5A, TPH1, TPH2 | ALDH1A1 377/4885KDM4E 2606/4885LMNA 2210/4885 |
| US-20070149545-A1 | Substituted indan derivatives | CBR3, CORO1C, REL | ALDH1A1 3381/4885KDM4E 3444/4885LMNA 4106/4885 |
| US-20030144291-A1 | Substituted indan derivatives | NR2C2, INSR, REL | ALDH1A1 1206/4885KDM4E 3565/4885LMNA 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.